Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Zendesk, which has had a footprint in Mid-Market since 2011, is officially out of the neighborhood with a new headquarters in ...

Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health, GSK, said: “At ViiV Healthcare we believe ... we need all types of funders, including corporate funders like ViiV, to support ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s intraday trade. The stock rose after the company reported its second quarter ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...

closing a critical gap in corporate sustainability. “We’re pleased to see GSK, Kering and Holcim lead the way by publicly adopting the world’s first science-based targets beyond climate; demonstrating ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019)-- -- RSV neutralizing antibodies for ...